Current strategies for different paclitaxel-loaded Nano-delivery Systems towards therapeutic applications for ovarian carcinoma: A review article
-
Published:2019-10
Issue:
Volume:311-312
Page:125-137
-
ISSN:0168-3659
-
Container-title:Journal of Controlled Release
-
language:en
-
Short-container-title:Journal of Controlled Release
Author:
Khalifa Alaa M.,
Elsheikh Manal A.,
Khalifa Amr M.,
Elnaggar Yosra S.R.ORCID
Subject
Pharmaceutical Science
Reference171 articles.
1. A systematic review of symptoms for the diagnosis of ovarian cancer;Ebell;Am. J. Prev. Med.,2016
2. Cancer statistics, 2009;Jemal;CA Cancer J. Clin.,2009
3. A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse;Vergote;J. Clin. Oncol.,2016
4. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial;du Bois;The Lancet Oncol,2016
5. Epidemiology of epithelial ovarian cancer;Webb;Best Pract Res Clin Obstet Gynaecol,2017
Cited by
69 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献